Combination use of
digoxin and other medications might lead to worse outcomes in patients with
atrial fibrillation (AF). We sought to investigate whether
digoxin-
amiodarone combination would lead to worse outcome than
digoxin alone in patients with AF. Adult patients with AF and received
digoxin treatment from random samples of 1,000,000 individuals covered by the National Health Insurance in Taiwan were included. Baseline characteristics including risk factors and medications were matched by propensity score (PS) in those with and without addition of
amiodarone treatment. A total of 5,040 AF patients taking
digoxin therapy was included. PS matching identified 1,473 patients receiving
digoxin-
amiodarone combination and 2,660 patients receiving
digoxin with a median follow-up of 1,331 days.
Digoxin-
amiodarone combination was associated with increased all-cause mortality (adjusted hazard ratio (HR): 1.640, 95% confidence interval (CI): 1.470-1.829, P < 0.001). The risk of mortality increased regardless of duration of combination. Risk of
sudden cardiac death was not increased in the combination group (HR: 1.304, 95% CI: 1.049-1.622, P = 0.017). Death due to non-arrhythmic
cardiac disease,
cerebrovascular disease, and other
vascular disease were higher in the combination group than the
digoxin group. In conclusion, in patients with AF,
digoxin-
amiodarone combination
therapy is associated with excess mortality than
digoxin alone.